

Quanterix Presenting at Canaccord Genuity 44th Annual Growth Conference

August 6, 2024

BILLERICA, Mass.--(BUSINESS WIRE)--Aug. 6, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue and Chief Financial Officer Vandana Sriram will speak in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on August 13, 2024, at 3:00 p.m., ET.

The presentation will be available virtually and participants can register using this link. The presentation will be available following the conference on Quanterix's website here.

To learn more about Quanterix, visit www.quanterix.com/about. To learn more about Quanterix's Simoa® technology, visit: https://www.quanterix.com/about. To learn more about Quanterix's Simoa® technology, visit: https://www.quanterix.com/about. To learn more about Quanterix's Simoa® technology, visit: https://www.quanterix.com/about. To learn more about Quanterix's Simoa® technology, visit: https://www.quanterix.com/about. To learn more about Quanterix's Simoa® technology, visit: https://www.quanterix.com/about. To learn more about Quanterix's Simoa® technology, visit: https://www.quanterix.com/about. To learn more about Quanterix's Simoa® technology, visit: https://www.quanterix.com/about. To learn more about Quanterix's Simoa® technology, visit: https://www.quanterix.com/about. To learn more about Quanterix's Simoa® technology, visit: https://www.quanterix.com/about. To learn more about Quanterix's Simoa® technology, visit: <a href="https://www.quanterix.com/about. To learn more about Quanterix's Simoa® technology is the simoa simple of the simoa simoa simple of the simoa simoa simple of the simoa simoa

About Quanterix

From discovery to diagnostics, Quanterix's ultra-sensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company's Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,900 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240806815882/en/

Media:

PAN Communications Maya Nimnicht 510-334-6273 quanterix@pancomm.com

Investor Relations:

Quanterix Francis Pruell (508)-789-1725 ir@quanterix.com

Source: Quanterix Corporation